Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology, Basic and Translational - In vitro and In vivo Oncology

Combinatorial effect of the PSMA targeted alpha therapeutic, [225Ac]-FPI-2265, and olaparib in a pre-clinical prostate cancer tumor model

Shekoufeh Almasi, Vishal Subramony, Alexander Nielsen, William Turnbull, Nicole Robinson, Sarah Marinacci, Jacqueline Ferreira, Kevin Chathely, John Forbes, Brigitte Thériault, John Valliant and Christopher Leamon
Journal of Nuclear Medicine June 2024, 65 (supplement 2) 241556;
Shekoufeh Almasi
1Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vishal Subramony
1Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Nielsen
1Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Turnbull
1Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole Robinson
1Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Marinacci
1Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacqueline Ferreira
1Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Chathely
1Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Forbes
1Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brigitte Thériault
1Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Valliant
1Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Leamon
1Fusion Pharmaceuticals
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 65 no. supplement 2 241556

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online June 9, 2024.

Copyright & Usage 
© 2024

Author Information

  1. Shekoufeh Almasi,
  2. Vishal Subramony,
  3. Alexander Nielsen,
  4. William Turnbull,
  5. Nicole Robinson,
  6. Sarah Marinacci,
  7. Jacqueline Ferreira,
  8. Kevin Chathely,
  9. John Forbes,
  10. Brigitte Thériault,
  11. John Valliant and
  12. Christopher Leamon
  1. 1Fusion Pharmaceuticals

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: June 2024 to April 2025

AbstractFullPdf
Jun 20246600
Jul 202421100
Aug 202421200
Sep 202418800
Oct 202415600
Nov 202417200
Dec 202411600
Jan 202512000
Feb 202512500
Mar 202512900
Apr 202514900
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 65, Issue supplement 2
June 1, 2024
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Combinatorial effect of the PSMA targeted alpha therapeutic, [225Ac]-FPI-2265, and olaparib in a pre-clinical prostate cancer tumor model
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Combinatorial effect of the PSMA targeted alpha therapeutic, [225Ac]-FPI-2265, and olaparib in a pre-clinical prostate cancer tumor model
Shekoufeh Almasi, Vishal Subramony, Alexander Nielsen, William Turnbull, Nicole Robinson, Sarah Marinacci, Jacqueline Ferreira, Kevin Chathely, John Forbes, Brigitte Thériault, John Valliant, Christopher Leamon
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 241556;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Combinatorial effect of the PSMA targeted alpha therapeutic, [225Ac]-FPI-2265, and olaparib in a pre-clinical prostate cancer tumor model
Shekoufeh Almasi, Vishal Subramony, Alexander Nielsen, William Turnbull, Nicole Robinson, Sarah Marinacci, Jacqueline Ferreira, Kevin Chathely, John Forbes, Brigitte Thériault, John Valliant, Christopher Leamon
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 241556;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Evaluating ΔFFNP-PET as an imaging biomarker of estrogen receptor α (ERα) functional status in preclinical models of ERα+ breast cancer with ESR1 mutations
  • PET Imaging Study of 68Ga-Labeled GZP Probe for Diagnosis and Therapeutic Monitoring of Acute-Graft-Versus-Host Disease (aGVHD) in Mice
  • Highly potent [225Ac]Ac-macropa-trastuzumab-PEG6-DM1 antibody drug radioconjugate against HER2-positive breast cancer xenografts
Show more Oncology, Basic and Translational - In vitro and In vivo Oncology

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire